Stock RVPH REVIVA PHARMACEUTICALS HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Reviva Pharmaceuticals Holdings, Inc.

Equities

RVPH

US76152G1004

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
2.99 USD +0.34% Intraday chart for Reviva Pharmaceuticals Holdings, Inc. -0.99% -41.94%
Apr. 15 Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia CI
Apr. 15 Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and seeks to commercialize therapeutics for diseases representing unmet medical needs. The Company’s pipeline focuses on the central nervous system, respiratory and metabolic diseases. Its pipeline includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Its lead drug candidate, brilaroxazine, is in clinical development and is to treat multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), attention-deficit/hyperactivity disorder (ADHD), behavioral and psychotic symptoms of dementia or Alzheimer’s disease (BPSD), and Parkinson’s disease psychosis. Brilaroxazine is also ready for clinical development for two respiratory indications, including pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Its RP1208 drug candidate is a triple reuptake inhibitor (TRI).

Number of employees: 15

Managers

Managers TitleAgeSince
Laxminarayan Bhat FOU
 Founder 59 20-12-10
Narayan Prabhu DFI
 Director of Finance/CFO 53 20-12-13

Members of the board

Members of the board TitleAgeSince
Parag Phoolchand Saxena CHM
 Chairman 69 20-12-13
Les Funtleyder BRD
 Director/Board Member 55 20-12-13
Laxminarayan Bhat FOU
 Founder 59 20-12-10
Purav Patel BRD
 Director/Board Member 42 20-12-13
Richard Margolin BRD
 Director/Board Member 73 20-12-13

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 27,918,560 22,958,005 ( 82.23 %) 0 82.23 %

Shareholders

NameEquities%Valuation
Laxminarayan Bhat
8.898 %
2,484,244 8.898 % 9 M $
Vedanta Capital LLC
8.241 %
2,300,876 8.241 % 9 M $
Armistice Capital LLC
6.318 %
1,764,000 6.318 % 7 M $
Vanguard Global Advisers LLC
3.492 %
974,982 3.492 % 4 M $
Millennium Management LLC
2.872 %
801,906 2.872 % 3 M $
Susquehanna Securities LLC
0.7368 %
205,712 0.7368 % 777 591 $
Geode Capital Management LLC
0.6405 %
178,806 0.6405 % 675 887 $
Polar Asset Management Partners, Inc.
0.5545 %
154,800 0.5545 % 585 144 $
EMC Capital Management LLC
0.4438 %
123,915 0.4438 % 468 399 $
The Colony Group LLC
0.4334 %
121,000 0.4334 % 457 380 $
NameEquities%Valuation
Arena Investors LP
-
85,000 - 53 635 $
Walleye Capital LLC
-
33,718 - 21 276 $
Walleye Trading LLC
-
25,727 - 16 234 $

Company contact information

Reviva Pharmaceuticals Holdings, Inc.

10080 North Wolfe Road Suite SW3-200

95014, Cupertino

+

http://www.revivapharma.com
address Reviva Pharmaceuticals Holdings, Inc.(RVPH)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.99 USD
Average target price
17.4 USD
Spread / Average Target
+481.94%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
REVIVA PHARMACEUTICALS HOLDINGS, INC. Stock Reviva Pharmaceuticals Holdings, Inc.
-41.94% 83.48M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RVPH Stock
  4. Company Reviva Pharmaceuticals Holdings, Inc.